Lescarden, Inc. is a publicly-owned biotechnology company focused on the development of natural biologic therapies for the chronic wound care,
dermatology and osteoarthritis markets. Lescarden’s research team, led for many years by one of its founders, Dr. John Prudden, is responsible for
the breakthrough studies conducted with bovine cartilage. These efforts brought the Lescarden team to the successful development of Catrix, a
product that is recognized for its therapeutically diverse applications, both systemic and topical. These applications include:
list view
grid view
